# Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes

Study · id `cardio:ct-nct05440591` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05440591](<https://clinicaltrials.gov/study/NCT05440591>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05440591

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

## Technical summary

Registry record NCT05440591. Randomized; no masking; primary purpose treatment. Start 2019-04-01 (actual); primary completion 2023-05-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT05440591, source copy `cardio:ctgov-nct05440591-2022-07-01`, retrieved 2026-10-26)
- Started: 2019-04-01 (actual) (ClinicalTrials.gov record NCT05440591, source copy `cardio:ctgov-nct05440591-2022-07-01`, retrieved 2026-10-26)
- Primary completion: 2023-05-10 (anticipated) (ClinicalTrials.gov record NCT05440591, source copy `cardio:ctgov-nct05440591-2022-07-01`, retrieved 2026-10-26)
- Completion: 2023-05-10 (anticipated) (ClinicalTrials.gov record NCT05440591, source copy `cardio:ctgov-nct05440591-2022-07-01`, retrieved 2026-10-26)
- Countries: Singapore (ClinicalTrials.gov record NCT05440591, source copy `cardio:ctgov-nct05440591-2022-07-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05440591-2022-07-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes
- Acronym: DMVascular
- Condition: Diabetes
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): MetFORMIN 500 Mg Oral Tablet
- Intervention (Drug): Dapagliflozin / metFORMIN Pill
- Lead sponsor: Tan Tock Seng Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: Tan Tock Seng Hospital (`cardio:org-tan-tock-seng-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial (`cardio:pubmed-42396722`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2f95d50537c01f85c80e3a7f90a41c828062bb3c382e965b4f3b6d4eb0d81221
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
